The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare ...

New data obtained has found cases soared over the four weeks to the end of November, with an extra 118 hospitalisations ...

The 15 drugs selected for negotiation are prescribed to 5.3 million Medicare beneficiaries to treat conditions ranging from ...

Novo is currently in a golden age of growth. Over the last five years, its trailing-12-month revenue grew by 109%, reaching ...

Former Trump administration health official Joe Grogan applauds Biden proposal that Medicare and Medicaid cover GLP-1 ...

U.S. Health and Human Services Secretary Xavier Becerra says “this is a big deal.” Drug companies oppose the program.

The U.S. government on Friday announced a list of 15 prescription medicines targeted for Medicare price negotiations for 2027 ...

Websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do ...

Novo Nordisk stock tumbled Friday after its weight-loss drug Wegovy landed on Medicare's next list of drugs to face price negotiations.

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.